Overview and Scope
Iron deficiency refers to a condition where the body lacks adequate iron, leading to decreased production of red blood cells and hemoglobin. Iron deficiency injectables refer to injectable medications or solutions used to treat iron deficiency. These injectable forms of iron allow for direct delivery of the iron into the bloodstream, bypassing the digestive system.
Sizing and Forecast
The iron deficiency injectable market size has grown rapidly in recent years. It will grow from $12.75 billion in 2023 to $14.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia treatments, bariatric surgery patients, pediatric and adolescent patients, growing pregnancy.
The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $20.68 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs,.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Segmentation & Regional Insights
The iron deficiency injectable market covered in this report is segmented –
1) By Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose
2) By Branded or Generics: Branded; Generics
3) By Application: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Applications
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
North America was the largest region in the iron deficiency injectable market in 2023. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of polycystic ovary syndrome (PCOS) is expected to propel the growth of the iron deficiency injectables market going forward. Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects people with ovaries, primarily women of reproductive age. Polycystic ovary syndrome (PCOS) leads to iron overload, which results in excessive blood loss during menstruation and makes patients anemic, which can be cured by injectable iron deficiency medications. For instance, in June 2023, according to the World Health Organization, a US-based specialized health agency, globally, polycystic ovary syndrome (PCOS) affects an estimated 8–13% of reproductive-aged women, among whom 70% remain undiagnosed. Therefore, the prevalence Of polycystic ovary syndrome (PCOS) is driving the growth of the iron deficiency injectables market.
Key Industry Players
Major players in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.
The iron deficiency injectable market report table of contents includes:
1. Executive Summary
2. Iron Deficiency InjectableMarket Characteristics
3.Iron Deficiency Injectable Market Trends And Strategies
4.Iron Deficiency Injectable Market analysis
5.Iron Deficiency Injectable Market Size And Growth
6.Iron Deficiency Injectable Segmentation
7.Iron Deficiency Injectable Regional And Country Analysis
.
.
.
27.Iron Deficiency Injectable Competitive Landscape And Company Profiles
28.Iron Deficiency Injectable Key Mergers And Acquisitions
29.Iron Deficiency Injectable Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Daiichi Sankyo Company Limited
- Pfizer Inc.
- Aetna Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
